Imaging and eye model for PVR study
Part of Eyes & vision clinical trials.
This study uses eye scans and computer models to better understand and predict a condition called proliferative vitreoretinopathy (PVR), which can cause vision problems after eye surgery. If you already took part in specific studies that collected your eye images, this trial may analyze those images with artificial intelligence (AI).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had eye images taken as part of the MORPH-1 or Cohort-NHS studies.
- You must have given consent for your images to be used in AI and other analyses.
- You do not need to come to the hospital for any new tests or treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at imaging and blood-based markers to better understand retinal detachment. It aims to find ways to predict how well the retina might reattach after surgery.
This trial is testing a new software tool that helps doctors see and assess different parts of the retina in eye scans. It aims to see how well the tool works in people with and without certain retina conditions.
This study tests whether a computer program (artificial intelligence) can use your eye scan images to help diagnose certain eye conditions. It might help catch problems earlier or more accurately, which could lead to better treatment.
This study looks at how certain enlarged blood vessels in the back of the eye change over time. By taking special images, researchers hope to learn more about these vessels. It might help if you have been told you have pachyvessels.
This trial studies whether a new, very high-resolution and high-speed eye scan can be used for people with eye problems or for healthy volunteers. It may help doctors better “see” eye structures more clearly to guide care.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
Hear when a new Proliferative Vitreoretinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.